FDA launches comprehensive review of rare disease drug approval process

On October 14, 2026, the FDA launched the Rare Disease Framework Initiative, embarking on a comprehensive review of its regulatory approval process for therapies targeting rare conditions. The effort follows a turbulent period marked by high-profile rejections, regulatory reversals, and leadership changes. Aiming to establish predictable, disease-specific evidence standards across review divisions, the agency seeks to address the 95% of rare diseases lacking approved treatments while incorporating patient and expert feedback.

FDA announces Rare Disease Framework Initiative

• ▪The FDA's Rare Disease Framework Initiative seeks to move away from a one-size-fits-all approach by evaluating clinical trial evidence based on small patient populations.
• ▪The FDA's framework builds on the plausible mechanism pathway introduced in November 2025 to expedite therapies when randomized trials are not feasible.
• ▪The FDA Rare Disease Framework Initiative aims to establish a fit-for-purpose regulatory framework across rare conditions affecting 30 million Americans.
• ▪Bloomberg News reported that the FDA is targeting February for initial recommendations under the Rare Disease Framework Initiative.
• ▪The FDA announced the Rare Disease Framework Initiative on October 14, 2026 to review and standardize its approach to rare disease drug regulation.

Leadership statements on the new initiative

• ▪Acting FDA Commissioner Kyle Diamantas stated that the regulatory system must evolve to anticipate the needs of rare disease patients and families.
• ▪Health Secretary Robert F. Kennedy Jr. stated on October 14, 2026 that the FDA must eliminate unnecessary barriers while maintaining rigorous safety standards.

Stakeholder reactions to the FDA framework

• ▪The Alliance for Regenerative Medicine stated that the framework's success in cell and gene therapy depends on upcoming FDA guidance on single-arm trials.
• ▪National Organization for Rare Disorders CEO Pam Gavin welcomed the FDA's focus on consistency across review divisions and inclusion of patient perspectives.

Framework scope and public feedback

• ▪The FDA scheduled a public meeting for October 28, 2026 at its Silver Spring, Maryland campus to gather feedback on the Rare Disease Framework Initiative.
• ▪In a white paper on the Rare Disease Framework Initiative, the FDA outlined plans to evaluate standards from pre-clinical trial engagement through post-marketing requirements.

Integration of existing rare disease programs

• ▪The FDA stated in a white paper that it aims to operationalize its existing rare disease initiatives into a consistently used cross-center regulatory approach.
• ▪The FDA highlighted existing programs including the Rare Disease Innovation Hub, CDER's ARC program, and the joint CDER-CBER RDEA pilot program.

Recent FDA rejections based on study design

• ▪In November 2025, the FDA disagreed with prior guidance allowing uniQure's Phase 1/2 Huntington's disease study to use a natural history external control.
• ▪The FDA issued a complete response letter in July 2025 for Capricor's deramiocel, citing the use of an externally controlled study as a major issue.

Leadership changes at the FDA

• ▪Former FDA Commissioner Marty Makary left the agency in May 2026 following unexpected drug rejections and delays that prompted congressional inquiries.
• ▪Vinay Prasad assumed leadership of the FDA's biologics center in 2025 and later departed the agency alongside former Commissioner Marty Makary.